Titan Pharmaceuticals, Inc. (de) (TTNP)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Titan Pharmaceuticals, Inc. (de) chart...

About the Company

titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

Exchange

NASDAQ

Website

https://www.titanpharm.com/

$0M

Total Revenue

39

Employees

$148M

Market Capitalization

-25.41

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TTNP News

We don't have any news on Titan Pharmaceuticals, Inc. (de) at the moment.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...